Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

EXTON, Pa., May 18 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) was honored with a Corporate Award at the National Organization for Rare Disorders (NORD) Annual Gala for its work in bringing Cinryze(TM) (C1 esterase inhibitor (human)) to market for a rare and devastating disorder -- hereditary angioedema (HAE).

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of swelling affecting the larynx, abdomen, face, extremities and urogenital tract. There are estimated to be at least 4,600 people with HAE in the United States.

"We are honored to be recognized by NORD for our work in bringing Cinryze to HAE patients in the U.S.," said Vincent Milano, ViroPharma's president and chief executive officer, "but what is even more gratifying for everyone at ViroPharma is making a difference in the lives of HAE patients who have literally been waiting for decades for this therapy."

Cinryze (C1 esterase inhibitor (human)) was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against HAE attacks in adults and adolescents. In February 2009, ViroPharma was granted priority review of a supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. If approved, Cinryze may be the first C1 esterase inhibitor available for the acute treatment for this condition. ViroPharma's Prescription Drug User Fee Act (PDUFA) date for the use of Cinryze for acute attacks in patients with HAE is June 3, 2009.

The NORD Gala is an annual event at which researchers and others are honored for significant achievements to im
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SAN DIEGO, California, USA (PRWEB) August 28, 2014 ... at the Department of Physics and Optical Science and ... at the University of North Carolina at Charlotte, and ... has been elected to serve as the 2015 Vice ... photonics. , SPIE 2014 President Philip Stahl announced recent ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency ... to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager ... plant owners and USDA-GIPSA inspection agencies that have a need ... take place in a matter of minutes with nothing but ... the feed and grain before accepting it, but they no ...
(Date:8/28/2014)... YORK , Aug. 28, ... that a new market research ... catalogue: Whole Exome ... Kits (Library Preparation, Target Enrichment), ... (Sequencing by Synthesis), by Application ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... flu is already tough, but it has become even harder in ... two antiviral drugs don,t slow it down anymore. Reporting their ... and Brigham Young move closer to understanding why not, and how ... changes. The two drugs, amantadine and rimantadine, are no longer ...
... Biosystems announced the release of its second generation of ... the company,s popular in vivo delivery product line: PEG-Liposome ... compatible for in vivo transfection of other negatively charged ... also offers custom encapsulation of target molecules into PEG-liposome ...
... Oct. 21 Sermo ( http://www.sermo.com ), the largest ... Report titled, " Physician Participation in the ESA REMS ... rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation ... the results, 83% of Hematologists/Oncologists view the ESA REMS ...
Cached Biology Technology:Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems 2Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2UMN researchers find animal model for understudied type of muscular dystrophy 2
... There are few things more irritating than a fly ... to the problem. They hang up a bunch of Roridula ... leaf,s hairs, the hapless pest is soon trapped by the ... story. Each R. gorgonias plant is home to a population ...
... model for studying the genetics of Angelman syndrome, a ... in one out of 15,000 births, has been developed ... Their research demonstrates that when a particular fruit ... behavioral dysfunctions similar to those experienced by humans whose ...
... Say the word "biofuels" and most people think of ... technology called gasification that,s getting a new look from ... and Iowa State University. By combining gasification with ... from a wide range of biomass, including distiller,s grain ...
Cached Biology News:Nothing stops an expert in the art of living 2Model for angelman syndrome developed by University of Texas at Austin biologists 2Turning waste material into ethanol 2
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
... pWEB::TNC™ Deletion Cosmid Cloning Kit enables you ... complete and unbiased primary cosmid library of ... nested deletion sublibraries. High efficiency cosmid library ... reproducible kit protocols. First, genomic DNA is ...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... Imager VersaDoc MP 4000 System is ... imaging system capable of supporting a ... fluorescence, chemiluminescence, densitometry, and chemiflourescence. ... allow imaging of multiplexed fluorescent samples, ...
Biology Products: